Array BioPharma

Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.

Key Information

Company type	Subsidiary
Traded as	Nasdaq: ARRY
Industry	Oncology Medication
Founded	1998; 27 years ago (1998)
Founder	Drs. Tony Piscopio Kevin Koch David Snitman K.C. Nicolaou
Headquarters	Boulder, Colorado , United States
Revenue	$173.8 million (2018)
Parent	Pfizer
Website	www.arraybiopharma.com
Show more

In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.^[1]

In November 2000, the company became a public company via an initial public offering.^[2]

In June 2019, Pfizer acquired the company for approximately $11 billion.^[3]

• MEKTOVI (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired by Pfizer
• TUKYSA (Tucatinib) - HER2 inhibitor - Approved 2020, owned by Seagen (Seattle Genetics)
• BRAFTOVI (Encorafenib) - BRAF inhibitor - Approved 2018, acquired by Pfizer
• KRAZATI (Adagrasib) - KRasG12C mutation inhibitor - Approved 2022, collaboration with Mirati Therapeutics
• KOSELUGO (Selumetinib) - MEK1/2 inhibitor - Approved 2020, licensed by Astrazeneca
• VITRAKVI (Larotrectinib) - TRK Inhibitor - Approved 2018, licensed by Loxo Oncology (Eli Lilly)
• RETEVMO (Selpercatinib) - RET inhibitor - Approved 2024, licensed by Loxo Oncology (Eli Lilly)
• GANOVO (Danoprevir) - HCV Protease inhibitor - Approved 2018 (in China), licensed by Roche